BioMarin Pharmaceutical Inc. has reported detailed positive Phase 3 results for VOXZOGO, or vosoritide, in children with hypochondroplasia, strengthening its attempt to extend an established achondroplasia medicine into a second genetically related skeletal dysplasia. The randomized CANOPY-HCH-3 study met its primary endpoint after 52 weeks, with children receiving vosoritide showing an adjusted annualized growth velocity advantage of 2.33 centimeters per year compared with placebo, while several secondary measures of linear growth also favored treatment.
The data have moved beyond an exploratory development milestone because BioMarin Pharmaceutical has already submitted a supplemental New Drug Application to the United States Food and Drug Administration seeking an expanded indication for hypochondroplasia. VOXZOGO is currently approved for children with achondroplasia in several major markets, but its use in hypochondroplasia remains investigational and has not yet been authorized by the FDA or other regulators for that condition.
CANOPY-HCH-3 was designed as a conventional confirmatory study rather than an uncontrolled rare-disease experiment. Approximately 80 children were planned for randomization, with participants treated for 52 weeks across 23 hospitals in nine countries. That design gives the regulatory package considerably greater weight than the earlier Phase 2 evidence, although the longer-term clinical implications of accelerating growth remain a central question as regulators assess the proposed new indication.
How strong was the Phase 3 growth effect produced by vosoritide in children with hypochondroplasia?
The primary endpoint was annualized growth velocity, an established measure of how quickly a child gains height over a defined period. After 52 weeks, BioMarin reported a least-squares mean treatment difference of 2.33 centimeters per year favoring VOXZOGO, with a p-value below 0.0001. The magnitude and statistical strength of the result leave relatively little doubt that vosoritide increased linear growth during the controlled study period.
The treatment effect was not confined to the primary endpoint. Children receiving VOXZOGO had an adjusted standing-height advantage of 2.35 centimeters compared with placebo after one year, while height Z-score improved by 0.39 standard deviations. Arm span also increased significantly, with an adjusted difference of 1.03 centimeters, providing an additional indication that the treatment effect was not limited to one method of measuring skeletal growth.
These secondary findings matter because relying solely on growth velocity could leave uncertainty over whether a faster short-term growth rate translated into an accumulating difference in actual stature. The standing-height result shows that separation between groups was already measurable after one year, while the height Z-score places that change in the context of age and sex.
Quality-of-life measurements moved numerically in favor of VOXZOGO, according to BioMarin, but the company did not characterize those results with the same statistical strength as the growth endpoints. That distinction is important because an increase in height should not automatically be interpreted as evidence of improved physical functioning, mobility or quality of life. Those broader outcomes require longer observation and appropriately designed analyses.
Why does FGFR3 biology make hypochondroplasia a logical extension of VOXZOGO’s achondroplasia franchise?
Hypochondroplasia and achondroplasia are distinct skeletal dysplasias, but both are strongly associated with activating variants in fibroblast growth factor receptor 3, or FGFR3. Excessive FGFR3 signaling inhibits endochondral bone growth, the process through which long bones lengthen during childhood. The biological overlap gives BioMarin a rational basis for investigating the same therapeutic pathway across both disorders.
Vosoritide is an analog of C-type natriuretic peptide that acts downstream of FGFR3 signaling. By counteracting excessive signaling through the pathway, the medicine is intended to promote endochondral bone growth while growth plates remain open. Its established activity in achondroplasia therefore provided a strong mechanistic foundation for testing whether the effect could extend to hypochondroplasia.
The diseases nevertheless should not be treated as interchangeable. Hypochondroplasia generally has a different spectrum of skeletal manifestations and can be harder to recognize clinically, sometimes resulting in diagnosis later in childhood. Disease severity is also variable, which means the magnitude of benefit and treatment goals may differ across patients.
CANOPY-HCH-3 attempted to address that variability through genetically confirmed diagnosis and predefined eligibility criteria. Participants were between three and under 18 years of age, had open growth plates and met a threshold for short stature, creating a population in which additional longitudinal growth remained biologically possible.
That selection means the results cannot simply be extrapolated to adults or children whose growth plates have closed. Any eventual regulatory label will define the eligible population, and commercial uptake will depend partly on how closely the final indication corresponds to the children evaluated in the pivotal program.
Does faster growth automatically mean that VOXZOGO changes the broader burden of hypochondroplasia?
This is the most important clinical limitation surrounding the otherwise strong Phase 3 result. Growth velocity is directly relevant to skeletal development, but hypochondroplasia can involve more than short stature. The condition may include disproportionate growth, orthopedic complications, neurological manifestations and other functional consequences that vary considerably between patients.
A statistically significant 2.33-centimeter annualized growth velocity advantage therefore establishes that vosoritide affects linear growth, but it does not independently demonstrate improvement across every complication associated with the disorder. Longer-term follow-up is needed to determine how treatment influences body proportions, physical function, skeletal morphology and other outcomes important to patients and families.
BioMarin is addressing that question through an open-label extension program intended to follow treated children over a substantially longer period, potentially extending through final adult height. Such follow-up can determine whether the first-year growth acceleration persists, decreases over time or produces a durable difference in eventual stature.
Final adult height will be particularly informative because annualized growth velocity is an intermediate endpoint. A medicine could accelerate growth during one phase of childhood without producing an equivalent difference at skeletal maturity if the effect diminishes or developmental timing changes. Continued follow-up can also provide a larger cumulative safety database for a treatment given daily over several years.
The longer-term program should additionally help clarify whether structural benefits extend beyond height. BioMarin is already studying measures such as body proportionality and arm span across its broader skeletal-conditions franchise. Those outcomes may become important in determining whether treatment provides benefits that are meaningful beyond a numerical increase on a growth chart.
What does the safety profile show after one year of daily VOXZOGO treatment?
BioMarin reported that safety findings in CANOPY-HCH-3 were consistent with the established profile of VOXZOGO in children with achondroplasia. Most adverse events were described as mild, and the company reported no treatment-related serious adverse events during the study. That is reassuring for a medicine potentially intended for long-term pediatric use, although a study of approximately 80 participants cannot identify every uncommon adverse event.
VOXZOGO’s existing prescribing information in achondroplasia includes the possibility of transient decreases in blood pressure. Injection-site reactions, vomiting, joint pain, abdominal symptoms and elevated alkaline phosphatase have also been observed in the approved population. Regulators evaluating the hypochondroplasia submission will consider whether the safety profile remains consistent when the medicine is used in a somewhat different genetic and clinical population.
Daily subcutaneous administration represents another practical issue. Long-term adherence may be more difficult outside clinical trials, particularly when therapy begins early in childhood and potentially continues for many years. Caregiver willingness, injection burden and persistence can consequently influence real-world effectiveness even if biological efficacy is maintained.
BioMarin has an advantage because VOXZOGO is already manufactured and commercialized globally. The company does not need to build an entirely new production, distribution and medical-education infrastructure for the potential hypochondroplasia launch, although it will still need to expand disease identification and treatment pathways.
How significant could hypochondroplasia become commercially for BioMarin Pharmaceutical?
BioMarin estimates that approximately 14,000 children with hypochondroplasia within its global commercial footprint could potentially be eligible for VOXZOGO. That company estimate should not be treated as guaranteed treated-patient volume because diagnosis rates, age, open growth plates, reimbursement and physician adoption will narrow the addressable population.
The opportunity is nevertheless meaningful because VOXZOGO has already become one of BioMarin Pharmaceutical’s most important growth assets. The company raised its 2026 VOXZOGO revenue guidance to between $1.0 billion and $1.05 billion after strong first-half demand, while the number of children receiving treatment globally increased by more than 20% year over year during the second quarter.
An additional hypochondroplasia indication could extend the product’s growth runway without requiring the risk and expense of launching an unrelated new molecule. The commercial organization already calls on many of the pediatric endocrinologists, geneticists and skeletal-dysplasia centers that would likely treat eligible hypochondroplasia patients.
Diagnosis could become a limiting factor. Hypochondroplasia can be subtler than achondroplasia and may not be recognized until later childhood, meaning expanded genetic testing and clinical awareness could be necessary to identify eligible patients before growth plates close.
Reimbursement will also require careful positioning. Payers are likely to examine not only the statistically robust improvement in growth velocity but the broader clinical value of treatment over years. Long-term data on final adult height, functional outcomes and quality of life could therefore influence commercial penetration well after an initial regulatory decision.
How are investors treating the new VOXZOGO indication?
BioMarin Pharmaceutical shares closed at about $65.68 on September 11, up 0.26% for the session and within a 52-week trading range of approximately $49.26 to $70.98. The stock did not produce an outsized reaction to the detailed CANOPY-HCH-3 publication, suggesting that investors had already incorporated much of the positive Phase 3 outcome and subsequent regulatory filing into expectations.
That muted response should not be interpreted as indifference to VOXZOGO. The drug is already central to BioMarin’s growth profile, and the company has raised full-year guidance as patient numbers increase. Investors are simultaneously assessing a broader business that includes the integration of acquired Amicus Therapeutics products, higher financing costs associated with that transaction and multiple rare-disease pipeline programs.
The hypochondroplasia expansion is therefore best understood as an incremental de-risking event for an established franchise rather than a binary company-defining catalyst. FDA acceptance and eventual review milestones may produce additional attention, particularly if BioMarin receives a defined action date for the supplemental application.
The regulatory question now looks considerably clearer than it did before CANOPY-HCH-3. VOXZOGO produced a statistically persuasive effect on its prespecified primary endpoint, supported by several secondary measures and a safety profile broadly consistent with existing experience. The remaining challenge is demonstrating that the growth advantage remains durable and clinically meaningful as children continue treatment toward adult height, which will determine whether the program becomes simply another label extension or a substantial new chapter in BioMarin Pharmaceutical’s skeletal-dysplasia franchise.
